HolderBook

BB BIOTECH AG

Reported holdings as of Q1 2019, from 2 quarterly filings.

This filer last reported in Q1 2019; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
924223
Reported value
$4.0B
Positions
35
Top 10 weight
64.7%
Filed
2019-05-13
Days after quarter end
43

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
IONIS PHARMACEUTICALS INCIONS$627.0M7,725,00015.76%+0.62pp2q-11.6%-$82.5M
INCYTE CORPINCY$311.4M3,620,0007.83%+0.07pp2q-4.9%-$16.2M
NEUROCRINE BIOSCIENCES INCNBIX$296.6M3,366,7867.46%-0.19pp2q+0.7%+$2.1M
VERTEX PHARMACEUTICALS INCVRTX$239.1M1,300,0006.01%-1.26pp2q-5.1%-$13.0M
SAGE THERAPEUTICS INCSAGE$218.7M1,375,2295.50%+1.28pp2qHELD
CELGENE CORPCELG$207.5M2,200,0005.22%+0.49pp2q-4.5%-$9.8M
AGIOS PHARMACEUTICALS INCAGIO$200.8M2,978,1345.05%+0.80pp2q+3.5%+$6.7M
ALEXION PHARMACEUTICALS INCALXN$177.7M1,314,4284.47%+0.37pp2qHELD
ALNYLAM PHARMACEUTICALS INCALNY$152.4M1,631,0893.83%+0.16pp2q+3.8%+$5.6M
ESPERION THERAPEUTICS INC NEESPR$141.4M3,522,9643.56%-1.44pp2q+3.8%+$5.2M
RADIUS HEALTH INCRDUS$135.2M6,781,6853.40%-0.15pp2q+1.1%+$1.4M
HALOZYME THERAPEUTICS INCHALO$134.0M8,322,8603.37%-0.53pp2qHELD
ARGENX SEARGX$112.9M904,7392.84%+0.12pp2q+2.3%+$2.5M
MODERNA INCMRNA$97.4M4,785,6812.45%+0.11pp2qHELD
MYOVANT SCIENCES LTDMYOV$85.9M3,597,8822.16%+0.27pp2qHELD
INTERCEPT PHARMACEUTICALS INICPT$78.0M696,9761.96%+0.10pp2q+21.1%+$13.6M
GILEAD SCIENCES INCGILD$74.3M1,142,2041.87%-0.80pp2q-14.3%-$12.4M
NEKTAR THERAPEUTICSNKTR$67.9M2,020,6761.71%+0.25pp2q+46.3%+$21.5M
EXELIXIS INCEXEL$67.5M2,835,0001.70%-0.09pp2qHELD
AKCEA THERAPEUTICS INCAKCA$67.4M2,377,6381.69%-0.61pp2qHELD
MYOKARDIA INCMYOK$65.8M1,264,9131.65%+0.28pp2q+44.2%+$20.2M
MACROGENICS INCMGNX$61.1M3,400,0001.54%+0.20pp2q+3.6%+$2.1M
WAVE LIFE SCIENCES LTDWVE$56.9M1,465,0021.43%-0.54pp2qHELD
VOYAGER THERAPEUTICS INCVYGR$54.9M2,865,8411.38%+0.52pp2qHELD
AUDENTES THERAPEUTICS INCBOLD$53.4M1,369,6041.34%+0.82pp2q+78.0%+$23.4M
ALDER BIOPHARMACEUTICALS INCALDR$37.8M2,766,0080.95%+0.04pp2qHELD
CRISPR THERAPEUTICS AGCRSP$28.9M810,4620.73%-newNEW
SCHOLAR ROCK HLDG CORPSRRK$27.8M1,476,8390.70%-0.24pp2q+15.4%+$3.7M
INTRA-CELLULAR THERAPIES INCITCI$26.8M2,200,0000.67%-0.13pp2qHELD
SANGAMO THERAPEUTICS INCSGMOQ$25.3M2,650,0000.64%+0.14pp2q+96.3%+$12.4M
KEZAR LIFE SCIENCES INCKZR$21.7M1,220,5030.54%-0.07pp2q+49.1%+$7.1M
G1 THERAPEUTICS INCGTHX$11.2M671,9250.28%-0.13pp2qHELD
CIDARA THERAPEUTICS INC COM NEWCDTXXXXX$6.1M2,295,2720.15%-0.02pp2qHELD
NOVAVAX INCNVAXXXXX$4.6M8,330,0000.12%-0.38pp2qHELD
HOMOLOGY MEDICINES INCFIXX$2.5M91,3360.06%-newNEW

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 67.6%Not classified 32.4%
 
SectorValueShare
Biotech & Pharma$2.7B67.6%
Not classified$1.3B32.4%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q1 2019$4.0B352145164.7%43
Q4 2018$3.1B34000064.0%43

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.